Lyell Immunopharma

Lyell Immunopharma

World Rank (Jan-05-2024)
12,587
Market Cap (Jan-05-2024)
0.501 Billion USD
World Rank (Jul-30-2023)
10,406
Market Cap (Jul-30-2023)
0.734 Billion USD
World Rank (Jan-07-2022)
7,342
Market Cap (Jan-07-2022)
1.534 Billion USD
World Rank (Jan-01-2021)
7,693
Headquarters Country
USA
Nasdaq / NYSE Code
LYEL
Market Cap (Mar-08-2026)
0.48
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
11 Million USD
Annual Operating Income in USD
-214 Million USD
Annual Net Income in USD
-250 Million USD
Annual Results for Period Ending
Dec-2022 ending year
Total Assets in USD
1,127 Million USD
Total Liabilities in USD
197 Million USD
Total Equity in USD
929 Million USD
Balance Sheet for Period Ending
Dec-2022 ending year
Business Sector
Healthcare
Biotechnology
Company Website
LYELL IMMUNOPHARMA
Company Profile
Lyell Immunopharma is a Biotechnology company in the fields of oncology and adoptive cell therapy. The company is in cell and gene therapy companies including Atara, Juno Therapeutics and Sangamo; oncology therapeutic development companies including Amgen, AstraZeneca, Genentech, Incyte and Seagen and cancer diagnostic companies including Genomic Health, GRAIL and Illumina. The headquarters is in USA.
Founded Year
2018
IPO Year
2021
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share